Copyright
©2009 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Nov 14, 2009; 15(42): 5371-5371
Published online Nov 14, 2009. doi: 10.3748/wjg.15.5371
Published online Nov 14, 2009. doi: 10.3748/wjg.15.5371
Hepatocellular carcinoma and evidence-based surgery
Alain Braillon, Hepatology and Public Health, University Hospital, 80000 Amiens, France
Author contributions: Braillon A wrote this paper.
Correspondence to: Alain Braillon, MD, PhD, Hepatology and Public Health, University Hospital, 80000 Amiens, France. braillon.alain@chu-amiens.fr
Telephone: +33-3-22667937 Fax: +33-3-22668198
Received: July 23, 2009
Revised: August 13, 2009
Accepted: August 20, 2009
Published online: November 14, 2009
Revised: August 13, 2009
Accepted: August 20, 2009
Published online: November 14, 2009
Abstract
Transplantation cannot be considered the most important therapeutic procedure for hepatocellular carcinoma (HCC). In France, no more than 2% of patients with HCC undergo a transplantation. Randomized controlled trial must assess the benefit to risk ratio of various potentially “curative” treatment procedures (transplantation, resection, radio-frequency ablation).
Keywords: Hepatocellular carcinoma; Evidence based medicine